Patents by Inventor Stuart B. Goodman
Stuart B. Goodman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11666445Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.Type: GrantFiled: June 17, 2020Date of Patent: June 6, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani, Chi-Chun Pan
-
Patent number: 11529393Abstract: Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NF?B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells—MSCs) comprising a nucleic acid that includes an NF?B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome.Type: GrantFiled: October 6, 2017Date of Patent: December 20, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Tzuhua Lin, Jukka Pajarinen, Stuart B. Goodman
-
Patent number: 11246890Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.Type: GrantFiled: April 1, 2019Date of Patent: February 15, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz
-
Publication number: 20200315801Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.Type: ApplicationFiled: June 17, 2020Publication date: October 8, 2020Inventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani, Chi-Chun Pan
-
Patent number: 10729816Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.Type: GrantFiled: March 18, 2016Date of Patent: August 4, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani
-
Publication number: 20190298774Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.Type: ApplicationFiled: April 1, 2019Publication date: October 3, 2019Inventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz
-
Publication number: 20190255151Abstract: Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NF?B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells—MSCs) comprising a nucleic acid that includes an NF?B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome.Type: ApplicationFiled: October 6, 2017Publication date: August 22, 2019Inventors: Tzuhua LIN, Jukka PAJARINEN, Stuart B. GOODMAN
-
Publication number: 20190015211Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: ApplicationFiled: May 16, 2018Publication date: January 17, 2019Applicant: The Board of Trustees of The Leland Stanford Junior UniversityInventors: David MYUNG, Lampros KOURTIS, Laura HARTMANN, Curtis W. FRANK, Stuart B. GOODMAN, Dennis R. CARTER
-
Publication number: 20180043062Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.Type: ApplicationFiled: March 18, 2016Publication date: February 15, 2018Inventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani
-
Publication number: 20160346089Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: ApplicationFiled: July 8, 2016Publication date: December 1, 2016Inventors: David MYUNG, Lampros KOURTIS, Laura HARTMANN, Curtis W. FRANK, Stuart B. GOODMAN, Dennis R. CARTER
-
Patent number: 9387082Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: GrantFiled: February 24, 2014Date of Patent: July 12, 2016Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans AffairsInventors: David Myung, Lampros Kourtis, Laura Hartmann, Curtis W. Frank, Stuart B. Goodman, Dennis R. Carter
-
Publication number: 20140172098Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Inventors: David MYUNG, Lampros KOURTIS, Laura HARTMANN, Curtis W. FRANK, Stuart B. GOODMAN, Dennis R. CARTER
-
Patent number: 8679190Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: GrantFiled: March 12, 2012Date of Patent: March 25, 2014Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans AffairsInventors: David Myung, Lampros Kourtis, Laura Hartmann, Curtis W. Frank, Stuart B. Goodman, Dennis R. Carter
-
Publication number: 20120232657Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: ApplicationFiled: March 12, 2012Publication date: September 13, 2012Inventors: David Myung, Lampros Kourtis, Laura Hartmann, Curtis W. Frank, Stuart B. Goodman, Dennis R. Carter
-
Publication number: 20090227487Abstract: Particle induced inflammatory diseases are treated by administration of an effective dose of an inhibitor of MyD88 adaptor protein.Type: ApplicationFiled: March 4, 2009Publication date: September 10, 2009Inventors: Jeremy Pearl, Ting Ma, William H. Robinson, R. Lane Smith, Stuart B. Goodman
-
Publication number: 20090088846Abstract: An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.Type: ApplicationFiled: April 17, 2008Publication date: April 2, 2009Inventors: David Myung, Lampros Kourtis, Laura Hartmann, Curtis W. Frank, Stuart B. Goodman, Dennis R. Carter
-
Unbalanced prosthetic device for providing side-dependent twisting-rotational axial-loading coupling
Patent number: 6299649Abstract: The present invention discloses a side-dependent prosthetic device. The side-dependent prosthetic device is a composite prosthetic device with a longitudinal direction. The composite prosthetic device includes a plurality of plies wherein each ply being composed of a plurality of reinforced fibers aligned in a ply orientational angle &thgr;i relative to the longitudinal direction of the prosthetic device, where i=1,2,3, . . . ,N and N being the number of the plies. The plurality of plies are laminated together for forming the prosthetic device wherein the ply orientational angles being arranged such that &thgr;1+&thgr;2+&thgr;3+ . . . +&thgr;N−0 thus forming an unbalanced composite prosthetic device.Type: GrantFiled: July 26, 1999Date of Patent: October 9, 2001Inventors: Fu-Kuo Chang, Hasan Yildiz, Stuart B. Goodman